Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers

NCT00126581 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00126581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00126581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of OSI-774 (Erlotinib) (NSC #718781) With or Without Carboplatin/Paclitaxel in Patients With Previously Untreated Adenocarcinoma of the Lung Who Never Smoked or Were Former Light Smokers
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2005
Completion date
November 28, 2017
Enrollment
188 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, lung adenosquamous carcinoma, malignant pericardial effusion, malignant pleural effusion, minimally invasive lung adenocarcinoma, stage iiib lung non-small cell cancer ajcc v7, stage iv lung non-small cell cancer ajcc v7